张伟滨教授是我国著名骨肿瘤专家,致力于恶性骨肿瘤临床与基础研究,在骨盆等四肢恶性骨肿瘤临床诊治方面颇有建树,尤其是针对复杂、巨大骨盆及肢体恶性肿瘤保肢治疗方面处于国内先进水平。参与制定了多部骨与软组织肿瘤专家共识。近年来聚焦于恶性骨与软组织肉瘤肺转移这一世界难题进行攻关,开展了多项临床研究,首创了化疗联合抗血管抑制剂肺转移围手术治疗模式,并创建了肉瘤肺转移手术时期、评估技术及抗血管抑制剂导致的气胸等多种创新治疗技术,大大推进了我国肉瘤肺转移临床研究和诊治技术的发展。"承担：1. 国家自然科学基金《阻断 PI3K/mTOR 信号通路诱导分化并靶向治疗骨肉瘤干细胞的分子机制研究》（项目批准号：81172550；2012.01-2015.12）；2. 上海市科委科技支撑计划生化重点科技攻关专项《重组人MNV-骨形态发生蛋白-2的II期临床研究生物学检测》子项目（编号：10431901202；2010.7-2013.9.）；3. 上海市科委“科技创新行动计划”科技攻关纳米项目《表面特殊微纳米羟基磷灰石生物学作用机理研究》（编号：14JC1492400；2014.9-2017.8.）；4.国家自然基金（面上）项目：《骨肉瘤干细胞外泌体启动并诱导纤维化特征肺转移前微环境的机制研究》编号：20YF1427300；5.市科委（自然基金）项目：《骨肉瘤外泌体诱导纤维化特征肺转移前微环境的分子机制及靶标研究》编号：20ZR1434000；6.国自然项目《基于共价键抑制剂库发现骨肉瘤新的靶标蛋白及其生物物学功能鉴定》编号：82141116；7. 中央资金/国家自然科学基金/面上项目《骨肉瘤细胞分泌VCAM1诱导CAFs活化重塑ECM介导肺微转移形成的机制研究》编号：82473015。8.上海交大（转化医学项目）,<骨肉瘤共价键小分子靶向药物的研发及作用机制>,编号：TMSK2021-145。 近五年发表论文： 1.MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma，IF: 5.682,通讯作者。 2. Establishment of a dynamic osteosarcoma biobank: Ruijin experience，IF:1.52， 通讯作者 3. A novel in vivo mouse intervertebral disc degeneration model induced by compressive suture，IF 3.905,通讯作者。 4. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma，IF:8.47，通讯作者 5. Development and analysis of long non-coding RNA-associated competing endogenous RNA network for osteosarcoma metastasis，IF:3.27，通讯作者 6. Impaired Limb Functional Outcome of Peripheral Nerve Regeneration Is Marked by Incomplete Recovery of Paw Muscle Atrophy and Brain Functional Connectivity in a Rat Forearm Nerve Repair Model，IF:3.59 7. Development and Validation of a Hypoxia-Associated Prognostic Signature Related to Osteosarcoma Metastasis and Immune Infiltration,IF:6.68，通讯作者 8. MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma，IF:6.68，通讯作者 9. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma，IF:6.5通讯作者 10. Construction and validation of a novel apoptosis-associated prognostic signature related to osteosarcoma metastasis and immune infiltration，IF:4.8，通讯作者 11. DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment，IF:15.15，通讯作者 12. Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection，IF:12.48，通讯作者 13. Superenhancers activate the autophagy-related genes Beclin1 and LC3B to drive metastasis and drug resistance in osteosarcoma,IF:9.92，通讯作者 14. The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma following a Favorable Tumor Response to Antiangiogenics Therapy，IF:3.39，通讯作者 15. CT-derived Radiomics Predicts the Efficacy of Tyrosine Kinase Inhibitors in Osteosarcoma Patients with Pulmonary Metastasis，IF:4.5，通讯作者 16. HIF-1α protects nucleus pulposus cells from oxidative stress-induced mitochondrial impairment through PDK-1，IF:7.1，通讯作者 17. Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis，IF:10.6,通讯作者 "